LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Home・Lista de Ações・CytoSorbents Corp

CytoSorbents Corp

Abrir

SetorSaúde

0.52 -7.14

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.5

Máximo

0.56

Indicadores-chave
By Trading Economics
Rendimento	-2.3M -5.5M
Vendas	-251K 9.2M
Margem de lucro	-59.526
Funcionários	129
EBITDA	-766K -3.7M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+29.31% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-2.7M 40M
Abertura anterior	7.66
Fecho anterior	0.52

Sentimento de Notícias

By Acuity

93%

326 / 346 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

0.705 / 0.771 Suporte e Resistência

CytoSorbents Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de mai. de 2026, 22:54 UTC

Ganhos

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 de mai. de 2026, 23:51 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 de mai. de 2026, 23:51 UTC

Conversa de Mercado

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 de mai. de 2026, 23:45 UTC

Conversa de Mercado

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 de mai. de 2026, 23:45 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

13 de mai. de 2026, 23:17 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 de mai. de 2026, 23:16 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 de mai. de 2026, 23:15 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 de mai. de 2026, 23:14 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 de mai. de 2026, 23:02 UTC

Conversa de Mercado

Ganhos

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 de mai. de 2026, 22:59 UTC

Conversa de Mercado

Ganhos

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 de mai. de 2026, 22:24 UTC

Ganhos

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 de mai. de 2026, 22:23 UTC

Ganhos

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 de mai. de 2026, 22:23 UTC

Ganhos

Xero FY International Revenue Growth 47%>XRO.AU

13 de mai. de 2026, 22:22 UTC

Ganhos

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 de mai. de 2026, 22:19 UTC

Ganhos

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 de mai. de 2026, 22:19 UTC

Ganhos

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 de mai. de 2026, 22:18 UTC

Ganhos

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 de mai. de 2026, 22:16 UTC

Ganhos

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 de mai. de 2026, 22:15 UTC

Ganhos

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 de mai. de 2026, 22:15 UTC

Ganhos

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 de mai. de 2026, 22:13 UTC

Ganhos

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 de mai. de 2026, 22:12 UTC

Ganhos

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 de mai. de 2026, 22:11 UTC

Ganhos

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 de mai. de 2026, 22:11 UTC

Ganhos

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 de mai. de 2026, 22:10 UTC

Ganhos

Xero Did Not Declare a Dividend>XRO.AU

13 de mai. de 2026, 22:10 UTC

Ganhos

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 de mai. de 2026, 22:09 UTC

Ganhos

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 de mai. de 2026, 22:00 UTC

Ganhos

Cisco to Shed Jobs for All-In AI Push -- Update

13 de mai. de 2026, 21:11 UTC

Ganhos

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Comparação entre Pares

Variação de preço

CytoSorbents Corp Previsão

Preço-alvo

By TipRanks

29.31% parte superior

Previsão para 12 meses

Média 0.75 USD 29.31%

Máximo 0.75 USD

Mínimo 0.75 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para CytoSorbents Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para CytoSorbents Corp - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

0.705 / 0.771Suporte e Resistência

All events are bearish.

Sentimento

By Acuity

326 / 346 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.